April 03, 2025

Study Reveals Psychiatric Sequelae Post-COVID-19

COVID-19 survivors showed a significantly higher risk of psychiatric disorders, according to a recent study.

Conexiant

April 02, 2025

Sleep Apnea Associated with Lung Cancer Risk

The impact of sleep apnea on lung cancer risk appears to be strongly influenced by biological sex, researchers find in a nationwide study of COPD patients.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Long-Term Antidepressant Use Affects Body Weight

"Given the global obesity epidemic and the widespread use of antidepressants, weight management and metabolic monitoring should be encouraged and integrated into depression follow-up guidelines alongside antidepressant prescriptions," the researchers concluded.

Conexiant

March 28, 2025

Night Owls Lose Most Sleep to Screens

New study links nightly screen use to later bedtimes, lower sleep quality, and nearly an hour of lost rest each week

Conexiant

March 26, 2025

State Eyes New Tools to Bolster Health Workforce

Proposals include licensure for community health workers, expanded provider roles, and Medicaid coverage adjustments to address staffing gaps and access barriers.

KFF Health News

March 24, 2025

Sex Differences in Asthma and COPD Hospital Admission Outcomes: Study

Females with asthma had 'higher odds of readmission within 30 and 90 days' compared with males, according to a new study on sex differences in asthma and COPD outcomes.

Conexiant

March 24, 2025

New State Model for Psilocybin Therapy

Read about the emergence of state-regulated psychedelic mushrooms in Colorado and their potential therapeutic applications.

KFF Health News

March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant